Compare BTU & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | LIVN |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United Kingdom |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2001 | 2015 |
| Metric | BTU | LIVN |
|---|---|---|
| Price | $24.07 | $71.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $32.83 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 2.9M | 790.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $3,861,500,000.00 | N/A |
| Revenue This Year | $17.96 | $9.79 |
| Revenue Next Year | $5.47 | $6.63 |
| P/E Ratio | ★ N/A | $179.70 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.62 | $41.02 |
| 52 Week High | $41.14 | $73.30 |
| Indicator | BTU | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 61.49 |
| Support Level | $15.67 | $60.76 |
| Resistance Level | $31.20 | $71.58 |
| Average True Range (ATR) | 1.04 | 2.78 |
| MACD | 0.09 | 0.99 |
| Stochastic Oscillator | 10.33 | 87.51 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.